--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...

Scientists at the Karolinska Institutet in Sweden have found a new region in the c-Myc oncogene that would allow the development of a binding compound to target it. Their discovery is based on a ...

There is increasing evidence that sustained oncogene expression may be required to maintain the cancer state, implying that therapeutic strategies that use transient pharmacological inactivation may ...

Cancer-associated genes called oncogenes are well known to stimulate cell growth and division — causing tumors to balloon and spread. But now, researchers at the Stanford School of Medicine and ...

UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals. The company is also exploring translational and commercial ...

TAIPEI and SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) ...

Could a natural check on cancer be used to stop the disease? It's possible, but to leverage a system that nature designed, we must first understand it. Researchers led by a team at Purdue University ...

Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex ...